LRC served as lead bankruptcy counsel to Argos Therapeutics, Inc. (“Argos”) in its chapter 11 proceeding in the United States Bankruptcy Court for the District of Delaware. Argos was an immune-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases. LRC advised Argos in all aspects of its chapter 11 case, including negotiating a stalking horse asset purchase agreement and preparing all operational motions in connection with the bankruptcy case. In addition, LRC, along with Argos’s other professionals, engaged in an extensive marketing process leading to a successful auction which resulted in an over-bid topping the stalking horse bid and increasing value to Argos’s stakeholders. The sale to the successful bidder was approved by the Court on January 23, 2019 and the sale closed on February 15, 2019.
Click on attorneys names below to see more representative matters.